Real World Data verify improved Treatment Results of Eltrombopag (Revolade®) from Novartis compared to other Second-line Therapies for Patients with Immune Thrombocytopenia (ITP)

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：75 / 75
页数：1
相关论文
共 45 条
  • [1] Real World Data show improved Treatment Results for Eltrombopag compared to other Second-line Therapies in ITP
    不详
    [J]. TRANSFUSION MEDICINE AND HEMOTHERAPY, 2019, 46 (01) : 59 - 59
  • [2] Real-World Use, Effectiveness and Safety of Romiplostim, Eltrombopag and Avatrombopag in Immune Thrombocytopenia: Data from the Norwegian ITP Registry
    Tomasello, Riccardo
    Garabet, Lamya
    Pettersen, Heidi
    Tjonnfjord, Eirik
    Tsykunova, Galina
    Pedersen, Torkild
    Tran, Hoa
    Napolitano, Mariasanta
    Ghanima, Waleed
    [J]. BLOOD, 2023, 142
  • [3] Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
    Cuker, Adam
    Buckley, Brian
    Mousseau, Marie-Catherine
    Barve, Aditya Anand
    Haenig, Jens
    Bussel, James B.
    [J]. ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2051 - 2058
  • [4] Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
    Adam Cuker
    Brian Buckley
    Marie-Catherine Mousseau
    Aditya Anand Barve
    Jens Haenig
    James B. Bussel
    [J]. Annals of Hematology, 2023, 102 : 2051 - 2058
  • [5] Evaluation of Treatment Patterns Among Patients with Newly Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP) Treated with Eltrombopag in Real World Setting in the US
    Stafkey-Mailey, Dana
    Roy, Anuja
    Lokhandwala, Tasneem
    Yuan, Jing
    Landsman-Blumberg, Pamela
    Siddiqui, Asif
    Ghaznawi, Farhat
    [J]. BLOOD, 2017, 130
  • [6] An Observational Study of Fostamatinib As Second Line Therapy in Adult Patients with Immune Thrombocytopenia (ITP) in Real-World Clinical Practice
    Hughes, David
    Numerof, Robert P.
    Zider, Andrea
    Chow, Donna
    Goel, Ruchika
    [J]. BLOOD, 2021, 138
  • [7] ECONOMIC BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) IN PATIENTS RECEIVING ELTROMBOPAG (EPAG) AND ROMIPLOSTIM (ROMI): REAL WORLD EVIDENCE FROM 26 US INSTITUTIONS
    Forsythe, A.
    Bhor, M.
    Roy, A.
    Portella M, Socorro O.
    Kwon, C.
    Tremblay, G.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A552 - A552
  • [8] Real World Results of Multiple Myeloma Patients - Low Mortality Rate from First-Line to Second-Line Treatment
    Keil, Felix
    Attalla, Petra
    Seebacher, Adelheid
    Burger, Sabine
    Koller, Elisabeth
    Sliwa, Thamer
    Laschan, Claudia
    Krauter, Andreas
    Pfeilstoecker, Michael
    Fillitz, Michael
    [J]. BLOOD, 2022, 140 : 12598 - 12599
  • [9] Real world results of multiple myeloma patients - low mortality rate from first-line to second-line treatment
    Keil, F.
    Attalla, P.
    Seebacher, A.
    Burger, S.
    Koller, E.
    Sliwa, T.
    Laschan, C.
    Krauter, A.
    Pfeilstoecker, M.
    List, A.
    Fillitz, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 180 - 181
  • [10] Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia:real-world data from a single medical center
    董喜凤
    [J]. China Medical Abstracts(Internal Medicine)., 2024, 41 (03) - 184
12345